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The evolving nature of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has necessitated periodic revisions of COVID-19 patient treatment and
discharge guidelines. Since the identification of the first COVID-19 cases in November
2019, the World Health Organization (WHO) has played a crucial role in tackling
the country-level pandemic preparedness and patient management protocols. Among
others, the WHO provided a guideline on the clinical management of COVID-19 patients
according to which patients can be released from isolation centers on the 10th day
following clinical symptommanifestation, with a minimum of 72 additional hours following
the resolution of symptoms. However, emerging direct evidence indicating the possibility
of viral shedding 14 days after the onset of symptoms called for evaluation of the current
WHO discharge recommendations. In this review article, we carried out comprehensive
literature analysis of viral shedding with specific focus on the duration of viral shedding
and infectivity in asymptomatic and symptomatic (mild, moderate, and severe forms)
COVID-19 patients. Our literature search indicates that even though, there are specific
instances where the current protocols may not be applicable ( such as in immune-
compromised patients there is no strong evidence to contradict the current WHO
discharge criteria.
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BACKGROUND
On the 27th of May 2020, the World Health Organization
(WHO) provided an update to guide the clinical management
of COVID-19, wherein criteria for discharging patients were
recommended (1). As part of the clinical control of COVID-
19, a COVID-19 infected person can be allowed to go home
(regardless of location or disease severity), 10 days following
clinical manifestations, with at least 72 additional hours whereby
no symptoms have been noted (without fever and without
respiratory symptoms). This is in contrast with the WHO’s
earlier (12 January 2020) recommendations which required the
patient to be clinically recovered and to have two negative reverse
transcriptase quantitative polymerase chain reaction (RT-qPCR)
results on consecutive specimens taken at least 1 day apart (2).
Even though the WHO affirms that its recommendations are
based on evidence that patients without symptoms may continue
to shed the virus for several weeks, the viral particles are not
infectious and are of no threat for subsequent transmission.
The main reasons that necessitated the May 3rd, 2020 discharge
guidelines included apparent challenges and lack of resources
in areas of intense transmission (1). Indeed, in some regions
with high SARS-CoV-2 transmission rates, implementation of
the earlier discharge protocols had been challenging (3). This
is largely due to limited laboratory supplies, equipment and
personnel, especially outside hospital settings. Furthermore,
long isolation periods for patients with positive PCR results
but without any symptoms were found to negatively affect
their physical and mental well-being (4). In several countries,
this was further compounded by insufficient contact tracing
and test material/labor to meet the first WHO discharge
recommendations (3).
Given the potential strengths and weaknesses of the May
2020 guidelines, it is important to interrogate the updated
recommendations and criteria based on scientific evidence
and context-specific operational challenges. In particular, it is
important to reflect and provide answers to these questions:
(1) Are RT-PCR tests reliable enough? (2) From which site
do we take specimens? (3) Is there a correlation between viral
load and disease severity & patient status (symptomatic and
asymptomatic)? (4) Does the duration of viral shedding correlate
with infectivity? Empirical evidence on the above questions
will help further guide and improve discharge protocols
that can shorten patient isolation and minimize transmission
risks of convalescing patients. This review critically analyses
existing literature on SARS-CoV-2 viral shedding dynamics and
infectivity in convalescing patients.
METHODS
Authors attempted to assess in-depth a multitude of COVID-19
reports in PubMed, Google Scholar and Scopus. The following
keywords were used as search terms: viral shedding, COVID-
19, SARS-CoV-2, transmission, infectivity, viral load, dynamics,
viral viability, and WHO discharge guidelines. The date of last
search was April 2021. Concerned about the delays between
completion of studies and their publication and taking into
consideration the high turnover of publications on COVID-19
pandemic, manuscripts on preprint servers were also considered
(Research Square medRxiv dimensions and BioRxiv). Articles
identified by the searches were reviewed along with any relevant
references cited within them. Articles were excluded if the full
texts were not available or if they were not published in English.
DYNAMICS OF SARS-CoV-2
Understanding the dynamics and duration of infectivity of SARS-
CoV-2 is critical in the setting up of protocols guiding public
health for quarantine, isolation and contact tracing. The period
of infectivity is the space of time within which a naive individual
may acquire the infection from an infected person (5). The
clinical spectrum of SARS-CoV-2 is very heterogeneous and the
viral RNA shedding patterns vary in terms of shedding duration
and viral load depending on the nature (e.g., age, sex) and status
(e.g., asymptomatic, pre-symptomatic, symptomatic) of patients,
severity of disease (e.g., mild and severe COVID-19), and type of
sample tested (e.g., samples of upper respiratory tract and lower
respiratory tract).
Viral Loads in Different Specimens
Viral loads are generally quantified via RT-qPCR. In most
studies, viral loads from upper respiratory tract samples peaked
at the time of symptom onset and lasted for a few days, but
gradually decreased over the following 1–3 weeks (6–8). Viral
loads from stool samples peaked 3–4 weeks after symptom
onset and followed an erratic pattern (6). Inconsistency in
reported data was noted in terms of viral load dynamics for
upper respiratory samples depending on the location where the
specimen was taken (9, 10). Indeed, few reports concluded on
higher viral RNA in nasal swabs (9) compared to others who
noted higher viral loads in throat specimens (10). However, the
conclusion from the study conducted by Zou et al. (9) needs
cross-verification since the sample size was only 18 patients. The
amount of viral RNA found in the upper respiratory tract, lower
respiratory tract (sputum) and fecal samples followed different
trends. Maximum viral load was noted in upper respiratory tract
(URT) samples within 1 week of symptom onset and decreased
rather consistently becoming practically undetectable 2 weeks
after symptom onset (7, 8). On the other hand, maximum
viral load in lower respiratory tract (sputum) samples were
noted later, on average 2 weeks after symptom onset (11, 12)
and displayed higher viral loads than upper respiratory tract
samples (10, 13). Lower respiratory tract (LRT) samples have
shown increased sensitivity compared to URT specimens (14–
16). Indeed, compared to URT (nasal and throat), LRT samples
resulted in the highest positive rate for all stages of COVID-
19 infection (14). However, the use of LRT specimens may be
limited by the fact that only a small portion of COVID-19 (28%)
patients produce sputum (17). Moreover, even though viral RNA
could not be detected in URT samples, LRT [bronchoalveolar
lavage fluid (BALF)] tested positive (14). Based on these studies,
detection of viral load in LRT samples may be a good strategy
to follow COVID-19 evolution particularly in patients displaying
low viral loads. However, we note the technical challenges
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associated with collection of sputum or BALF, especially in
patients who are not intubated.
Variation of Viral Loads and Infectivity With
Disease Severity or Presence/Absence of
Symptoms
Viral load was directly linked with disease severity with higher
viral loads leading to severe forms of the infection (6, 18). Indeed,
in line with Zheng et al. (6), Liu et al. (18) found that the average
viral load in severe cases (n = 76) was higher than in mild cases.
Consequently, patients with severe COVID-19 infection had
significantly higher viral loads in respiratory samples compared
to those presenting with mild symptoms. In addition, Zheng et al.
(6), noted no significant difference in viral loads in stool and
serum samples between patients with mild and severe disease
(6). Mild cases correlated with early viral clearance while patients
with severe symptoms continued shedding the virus for a longer
period of time (6, 18). Indeed, RT-PCR results were repeatedly
negative for 90% of these patients by day 10 post-symptom-
onset in comparison to severe cases, whereby RT-PCR results
were positive at or beyond day 10 post-onset (18). Thus, these
studies suggest that the initial viral load impacts on the length of
hospital stay. However, both studies display limitations such as
insufficient sample size. In addition, the viral load is dependent
on the quality of collected samples and hence the viral load level
reported in the studies only partly reflects the amount of virus
present in the body. And finally, viral shedding was assessed
through PCR tests and the latter cannot distinguish between
viable and non-viable virus and does not reflect the replication
level of the virus in different tissues. Taken altogether, there is no
clear evidence to conclude on the relationship between viral load
and infectivity.
With respect of viral load and disease severity, there is
evidence supporting that higher viral load leads to severe cases.
The viral load of sputum specimens collected from the lower
respiratory tract and tested at baseline was closely linked to
disease severity (19). In particular, patients displaying a higher
baseline viral load were more likely to develop a severe form of
COVID-19. This important observation suggests that the early
administration of antiviral treatment can reduce the risk of
disease progression and mortality.
Some studies report little or no difference in viral loads
between pre-symptomatic, and those displaying and not
displaying symptoms (20, 21). For instance, Arons et al. (22)
found almost similar viral loads between asymptomatic and pre-
symptomatic patients with themedian cycle threshold (Ct) values
of 25.5 and 23.1, respectively, (lower Ct values infer higher viral
loads) (22) and therefore the use of symptom based strategies
is insufficient in the prevention of SARS-CoV-2 transmission.
On the other hand, average Ct values for asymptomatic patients
was significantly higher compared to those in the early stages
of infection (23). Both symptomatic and asymptomatic groups
displayed the same time frame of viral shedding (7 vs. 8 days)
which suggests that patients without COVID-19 symptoms can
still transmit the virus. Moreover, two studies confirmed the peak
of transmissibility near, and even before symptom onset (24, 25).
Even though a reduction in infectivity was noted in symptomatic
patients 7–10 days after onset of symptoms (8), viable virus could
still be isolated from upper and lower respiratory samples 13 and
18 days, respectively, after symptom onset (18, 22).
SARS-CoV-2 infection is primarily diagnosed based on
detecting the presence of viral RNA by molecular testing,
usually by RT-PCR in a specimen produced by the patient.
However, detection of viral RNA does not necessarily mean
that a person is infectious (26). Determination of the presence
of viable virus may be accomplished by monitoring the ability
of SARS-CoV-2 to replicate in laboratory-based cell culture.
It is however important to know whether the infected case
has mild-to-moderate symptoms or are patients with severe-to-
critical illnesses, or immunocompromised. Some studies have
provided evidence to suggest that COVID-19 patients with mild-
to moderate illness are highly unlikely to be infectious beyond
10 days from symptom onset (19, 27). On the contrary, current
evidence also indicates that patients with severe-to-critical illness,
and those who are immunocompromised, may be infectious for
a prolonged period, possibly for 20 days or more (28–30). All
these studies point to the fact that one should consider disease
severity, viral loads as well as immunosuppression status of the
patients involved before determining whether a case should be
quarantined according to WHO standards.
Dynamics of Transmission
At the early stage of COVID-19 infection, an innate immune
response characterized by interferon and cytokines is triggered.
This slows down the replication and spread of the virus, until
the adaptive immune response (humoral and cellular) starts to
clear the infection. Variation in the time of activation of the
adaptive immune response in different individuals implies that
the SARS-CoV-2 virus can continue replicating and remains
viable (31). In a recent study, it was found that interferons
play a key role in suppressing the virus in the upper airway,
while macrophages are primarily responsible for viral clearance
in the lungs, mononuclear phagocyte system (MPS), and other
systemic sites (32). Therefore, the rate at which lung and MPS
macrophages clear the virus influences the viral load in both the
lungs and the plasma (32). In patients with defective immune
systems, viral clearance will depend on the excretion of the virus
through the bile duct, which can take weeks.
In a case series conducted by Vetter et al. (33), the
authors monitored the shedding of viral SARS-CoV-2 RNA
and characterized the immune response kinetics. Strong innate
responses was noted characterized by an increase in type
I interferon and proinflammatory cytokines, as well as a
significant increase in intermediate monocytes with activation,
differentiation, and migration patterns as from 2 days following
symptom onset in all patients irrespective of disease severity.
Infectious viral shedding was noted only during the early acute
phase of disease i.e., in the first week after symptom onset (innate
immune response). All patients displayed cellular and humoral
adaptive responses. Indeed, T-cell immune response was noted
in all patients. However, the frequency of activated CD8T cells
was lower in patients with mild symptoms. Overall, the study
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supported most recommendations, which advise isolation for a
minimum of 10 days, even in patients with mild symptoms.
A seroprevalence study was conducted within selected
locations in Ghana to estimate the level of exposure of SARS-
CoV-2 in individuals across a wide socioeconomic range.
Using a strip-in-cassette lateral flow type RDT which separately
detects IgM and IgG antibodies against the nucleocapsid
protein of the virus, 252/1,305 persons tested positive for
either of the antibodies or both (34). Exposure rates in August
2020 revealed a significantly higher level amongst persons
of lower income, lower educational level and those engaged
in informal employment. Between October and December
2020 there was no apparent increase in exposure rates
indicating either a reduction in transmission intensity or loss
of circulating antibody responses. In a more recent survey
conducted in February 2021 during Ghana’s second wave
of infection, rates of exposure in persons of higher income
almost doubled, leading to the loss in exposure stratification
according to socioeconomic status, albeit most of the cases
remaining asymptomatic.
Cheng et al. (24) reported a higher risk of infection at the
onset of infection with the risk reducing at later stages of the
disease. This observation was confirmed with empirical evidence
of increased viral loads measured in throat swabs concomitant
with symptoms which reduced to lower viral loads toward
day 21 (26). Other (27) studies report that careful follow up
among close contacts with asymptomatic COVID-19 infections
did not differ whether the infected person had symptoms or
not. Oma et al. (35), found that nasal shedding preceded fecal
shedding and calves shedding BCoV RNA after 21 days of
infection did not infect sentinel animals supporting the fact that
prolonged shedding of BCoV RNA does not necessarily indicate
transmission potential.
According to Kissler et al. (36), the transmission dynamics of
SARS-CoV-2 is influenced by seasonal variation in transmission,
the longevity of immunity, and the degree of “protection”
provided as a result of exposure to other coronaviruses, as
well as the frequency and timelines of control measures. Walsh
et al. (37) summarized major findings from 113 studies on the
evolution of SARS-CoV-2 viral load with time as well as the
time frame during which the patient remains infectious. From
evidence on the detection pattern and viral load of SARS-CoV-
2 over the course of an infection (including any asymptomatic
or pre-symptomatic phase), and the duration of infectivity, it
was found that maximum viral RNA could be detected in upper
respiratory tract samples few days after the onset of symptoms or
during symptom onset. Around 2 weeks after symptom onset, no
viral RNA could not be detected at all. Sputum samples showed
higher viral loads, and persisted for longer time. Prolonged
viral RNA detection in fecal specimens was noted. However,
no study has been found whereby the duration of infectivity
was definitively measured. Indeed, COVID-19 patients cannot
transmit live virus during the entire period of viral RNA detection
since the presence of viral ribonucleic acid may not necessarily
indicate transmissible live virus. SARS-CoV-2 viral RNA load
from respiratory tract samples displayed a rather consistent trend
over the course of COVID-19 infection.
Zuo et al. (38) assessed the variation in SARS-CoV-2
transcriptional activity and tried to correlate the latter with
changes in fecal microbiome. SARS-CoV-2 viral RNA samples
were found in stool samples of 46.7% of the COVID-19 positive
patients. Forty two percent of these patients showed active
viral infection signature for a period of up to 6 days after
clearance of SARS-CoV-2 from respiratory samples. The viral
metagenome profile of all patients showed higher coverage (p
= 0.0261) and density (p = 0.0094) of the 3′ end of SARS-
CoV-2 genome compared to the 5′ end even if the patients
did not display GI symptoms. Moreover, the gut microbiota
of COVID-19 patients with GI infection showed increased
amounts of opportunistic pathogens, as well as reduced salutary
bacterial content. This important study showed the persistence
of transcriptional activity of viral infection and replication in
the gut even after clearance of SARS-CoV-2 from respiratory
samples. Furthermore, the authors deciphered for the first
time, the signature of active gut viral infection in COVID-
19 patients even in the absence of GI symptoms, suggesting
“quiescent” GI infection of SARS-CoV-2 following recovery
from COVID-19.
Transmission Potential and Shedding of
SARS-CoV-2 in Convalescing Patients
Several studies have been conducted regarding viral shedding
in nasopharyngeal swabs, tears, urine and excreta of severe,
mild, and asymptomatic COVID-19 cases. Nonetheless, there
are still knowledge gaps regarding the viral shedding dynamics
during the convalescent phase in COVID-19 patients with mild
and severe symptoms. Recent studies suggest that asymptomatic
COVID-19 carriers may be as contagious as symptomatic (mild
and severe) patients, and therefore may play an important
role in transmission through viral shedding (39–41). However,
in all these studies, viral RNA was detected via PCR and
not via viral culture as a result of which it is difficult to
conclude on whether the detection of viral RNA by RT-PCR
was related to viable virus or shedding of remnant non-
viable genetic material. Indeed, detection of viral subgenomic
RNA correlated poorly with shedding of infectious virus.
These RNAs are produced only in actively infected cells and
are not packaged into virions. Subgenomic RNAs were still
detected when virus cultures turned negative. This could indicate
that active replication continues in severely-ill symptomatic
COVID-19 patients after seroconversion and after shedding
of infectious virus has stopped. Possibly, infectious virions
are produced but are directly neutralized by antibodies in
the respiratory tract. On the other hand, the half-life of viral
subgenomic RNAs is not known in COVID-19 and these
RNAs may still be detected once replication has stopped. In
addition, asymptomatic patients recruited in the studies may
not be a good representation due to false-positives. Despite
limitations presented by these studies, the potential of SARS-
CoV-2 viral transmission via asymptomatic patients cannot
be underestimated. Therefore, an understanding of the viral
burden and transmission potential of patients whose symptoms
have resolved through larger epidemiologic investigations will
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be useful to design appropriate strategies for epidemiological
management of the disease.
COVID-19 patients displaying mild symptoms were assessed
for any unusual signs and their symptoms were correlated
with the viral shedding period. RT-PCR was performed every
2–7 days, with the duration of viral shedding ranging from
the day of first diagnosis to the day before the first negative
test. On average, viral shedding lasted for 24.5 days. According
to this study, it was evident that all patients presenting with
chest pain and sputum shed the virus significantly longer than
patients without these symptoms. Zhou et al. (42) studied the
risk factors of in treatment facility’s death rate for patients
infected with SARS-CoV-2, the duration of clinical symptoms,
viral shedding, and the associated differing laboratory findings
in the course of hospitalization using a retrospective multi-
center cohort approach. A total of 191 study subjects were
successfully followed up to the end of the study. Out of these,
54 patients died whereas 137 recovered and were discharged.
The patients’ ages ranged between 18 and 87 years, and about
half of them had comorbidities. The average duration of illness
to discharge was 22 days (IQR 18–25), whereas the average
time to mortality was 18.5 days (IQR 15–22). For survivors,
viral RNA was detectable through a duration of 20 days from
the onset of illness. However, in non-survivors, viral RNA
was detectable until death. The longest and shortest observed
duration of viral shedding among survivors was 37 and 8 days,
respectively. For patients who received anti-viral therapy, the
number of days of viral shedding differed slightly according
disease status. For those who had severe illness viral shedding
persisted for 19 days (17–22) whereas for patients with critical
illness status their viral shedding persisted for 24 days (22–
29, 43). Shortcomings of this study included (1) the lack of
effective antivirals, inadequate adherence to standard supportive
therapy, and high-dose corticosteroid use, (2) limited frequency
of respiratory specimen collection, (3) lack of quantitative viral
RNA detection, (4) limited sample size, and (5) late transfer
of patients to hospitals. Nevertheless, the authors argue that
this study is crucial to consider in patient management during
isolation and the guidance concerning the length of antiviral
treatment given that effective antiviral treatment may improve
clinical outcomes in COVID-19.
Yan et al. (44) assessed the factors associated with long-
term viral shedding and effect of lopinavir (LPV) or ritonavir
(r) treatment on hospitalized COVID-19 patients in China.
A comparison of the clinical features and SARS-CoV-2 viral
shedding was conducted between patients treated with and
without LPV/r. SARS-CoV-2 RNA could be detected for amedian
duration of 23 days from symptom onset. Older age and the lack
of LPV/r treatment were identified as independent risk factors
for long and persistent viral shedding. Indeed, patients treated
with LPV/r within the first 10 days of symptom onset showed
significantly shorter viral shedding duration compared to those
who did not receive LPV/r treatment (median 19 vs. 28.5 days).
The work of Yan et al. (44) concluded that administration of
LPV/r at an early stage of SARS-CoV-2 infection could reduce
the duration of viral shedding.
EXTRA-LONG DURATION OF VIRAL
SHEDDING/VIRAL RNA DETECTION
Li et al. (45) observed persistent shedding of SARS-CoV-2 60
days from onset of typical symptoms in a 71-year old Chinese
woman with prolonged shedding 36 days after recovery. This
observation suggested that asymptomatic, mildly symptomatic
and recently recovered patients may require prolonged isolation.
However, since the report by Li et al. (45) is based on a single
patient, further investigations based on larger cohorts will be
required to support this conclusion. In another study (46),
characterization and subsequent analysis of epidemiological,
clinical, laboratory, etiologic detection and radiological features
of COVID-19 demonstrated that for the moderate form of
COVID-19, individuals could shed viral particles for up to 25
days. Limitations of this study consisted of the following: (1) lack
the data during the first week of infection as most patients were
transferred from other hospitals, (2) limited frequency of sample
collection and the lack of quantitative viral RNA detection, and
(3) lack the data for stool samples. Man et al. (47) reported
viral shedding prolongation in a kidney transplant patient with
COVID-19 pneumonia on days 57 and 63 which surprisingly
turned out positive after relief of symptoms. This study also
suggested that recovered patients may shed viruses for a median
duration of 20 days. The longest reported duration of viral SARS-
CoV-2 RNA shedding from upper respiratory tract was 83 days
(45). The median duration of viral shedding from the time of
onset of symptoms in upper respiratory tract samples was 19 days
(IQR: 14–25 days) compared to 34 days (IQR: 24–40 days) in
lower respiratory tract samples (48). SARS-CoV-2 RNA seemed
to persist longer in lower respiratory tract samples compared to
upper respiratory tract samples (6, 49).
Liu et al. (11) successfully related the viral load to the viral
shedding period whereby higher viral load in severe COVID-
19 cases led to longer viral shedding period. Indeed, upper
respiratory tract specimens tested negatively 10 days after
manifestation of symptoms in 90% of mild cases in contrast
to severe cases where tests remained positive for a longer time
(11). In addition, the median duration of viral detection in
pre-symptomatic patients was 12 days compared to 6 days in
asymptomatic ones (50). Moreover, viral RNA could be detected
for longer time in males (vs. females) and in older patients
possibly due to differences in immune status/ hormone levels and
increased ACE-2 concentrations (6).
Children with mild COVID-19 were clinically assessed at
Wuhan Children’s Hospital, Wuhan, China and their laboratory
test results were also investigated and correlated with viral
shedding (51). On average, 6-year old children shed SARS-CoV-
2 virus for 15 days as calculated from the onset of COVID-19
to hospital discharge. This time frame was smaller in patients
without symptoms compared to those presenting symptoms (11
vs. 17 days). Age <6 years [odds ratio (OR) 8.94], hypersensitive
C-reactive protein level >3.0 mg/L (OR 4.89) and pneumonia
(OR 8.45) correlated with a higher probability of symptomatic
infection. Children displaying COVID-19 symptoms, fever as a
result of pneumonia and lymphocyte concentration<2.0× 109/L
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shed SARS-CoV-2 virus for longer time. Lu et al. (51) suggested
that close follow-up of symptoms could be associated with viral
shedding in COVID-19 infected children.
Park et al. (52) determined the persistence of SARS-CoV-
2 virus in patients displaying symptoms and also assessed the
duration of RNA detection in nasopharyngeal/oropharyngeal
swabs or sputum or saliva in 6 patients using real-time reverse
transcriptase polymerase chain reaction. SARS-CoV-2 virus
could be detected in patients at a median time of 34 days
(11, 22–66) following their hospitalization. Furthermore, the
virus could still be detected in patients even after symptom
resolution for a median duration of 26 days (9–48). In one of the
patients, viral RNA could persistently be detected until 67 days
of hospitalization i.e., 30 days following resolution of symptom.
This is the longest time period of SARS-CoV-2 detection and
reiterates the importance of long-term patient follow up even
after symptom resolution.
Li et al. (53) assessed the dynamics of viral RNA shedding at
various stages in COVID-19 infected patients. Pre-symptomatic,
asymptomatic and mildly symptomatic patients showed median
SARS-CoV-2 shedding of 11.5, 28, and 31 days, respectively.
38.9% of patients displayed persistent shedding after hospital
discharge. Antibodies to SARS-CoV-2 and viral RNA could
be simultaneously detected in 27.8% of patients during the
convalescent phase. Long-term RNA shedding was noted in
patients presenting mild symptoms as well as in asymptomatic
ones. The authors suggested that specific antibody production
may not imply SARS-CoV-2 clearance after hospital discharge
and this is an important point to be considered when deciding
on strategies to better control SARS-CoV-2 infection.
Lee et al. (40) reported that in a retrospective cohort of 201
symptomatic COVID-19 patients, the median RNA shedding
time was 14 days (IQR 9–18) and 38.3% of patients showed
intermittent viral shedding. The duration of shedding displayed
an inverse correlation with plasma levels of T-cell cytokines IL-
1β and IL-17A at the initial phase of infection, and the levels
of pro-inflammatory cytokines were lower in patients during
intermittent shedding. The less active T-cell responses at the start
of COVID-19 infection could be correlated with prolonged viral
RNA shedding and thus early immune responses help to manage
viral load and to prevent viral RNA shedding.
In a recent study conducted on 20 immunocompromised
COVID-19 patients, it was found that viral shedding occurred for
up to 78 days after symptom onset (54). Interestingly, follow-up
specimens taken from 5 patients showed the presence of viable
virus post 8, 17, 25, 26, and 61 days after the onset of symptoms.
Three of these patients underwent allogeneic hematopoietic
stem-cell transplants (2 patients) or CAR T-cell therapy (1
patient) within the previous 6 months. Overall, this important
study highlights the fact that immunosuppressed patients may
continue shedding viable SARS-CoV-2 for at least 2 months
and thus the current WHO discharge guidelines may not be
convenient for these patients.
Kim et al. showed that the time from disease onset to viral
clearance in culture with the time to clearance in real-time RT-
PCR tests was not in agreement with each other (55). In fact,
following viral cultures and real-time RT-PCR, the median time
for viral clearance was found to be 7 and 34 days, respectively.
Positive viral cultures were obtained only in samples with a cycle-
threshold value of 28.4 or less. They noted that as the time from
symptom onset increased, the probability of culture positivity
decreased. However, conclusions from this study need to be
cross-checked in larger and more diverse groups of patients due
to the small sample size, inconsistency in timing of sampling, and
relatively mild illness of the enrolled patients.
VIRAL VIABILITY AND INFECTIVITY IN
DIFFERENT SCENARIOS
Even though evidence showed that SARS-CoV-2 viral shedding
occurs both in patients with and without symptoms, the
correlation between transmissibility/infectivity and detectable
viral RNA remains unclear (56). This is due to the fact that a
positive RT-PCR result does not necessarily imply the possibility
of viral transmission as this test cannot differentiate between
infective and inactive virus and a higher amount of viral RNA
does not necessarily imply greater infectivity. Another aspect to
be considered in this matter is seroconversion. It is still not clearly
understood how seroconversion is related to infectiousness.
Wölfel et al. (8) and Liu et al. (11) noted the persistence of viral
shedding after seroconversion and reported on the successful
culture of SARS-CoV-2 virus after the detection of antibodies.
Only few studies have correlated RT-PCR test results with
viral cultures and infectivity. Arons et al. (22) could successfully
isolate viable viruses from specimens collected 6 days before
to 9 days after the appearance of first typical symptoms. These
authors reported that 67.2% of specimens collected from the
upper respiratory tract resulted in positive viral cultures. Viral
load values (Ct) as low as 34.3 gave positive culture growth.
In addition, positive viral cultures could be obtained from
asymptomatic, pre-symptomatic and symptomatic patients (22).
Detection of infectious isolates depended on the sample site.
Indeed, SARS-CoV-2 virus could be readily isolated from throat
and lung derived samples in contrast to stool samples despite
high viral loads (8). Despite detection of SARS-CoV-2 RNA
by PCR 20 days after onset of symptoms, isolation of the
latter was not possible even though viral loads were high (57).
Moreover, viral culture positivity rate decreased progressively
with increasing Ct values until no culture could be obtained with
Ct values higher than 34 targeting the E gene.
The extent and length of infectious virus replication should be
considered when evaluating the possibility of viral transmission
which will in turn guide decisions regarding patient discharge
and isolation. Qualitative or quantitative viral RNA tests have
been used extensively as a potential marker for infectious
coronavirus since RNA detection is more sensitive than virus
isolation. But this can be problematic because, shedding viral
RNA may not necessarily be synonymous to shedding whole
viruses. Even though assessing the potential infectivity is a labor-
intensive process, it is not possible to estimate the average time
frame of viral RNA shedding by investigating the presence of
SARS-CoV-2 viral RNA in patient samples as the presence of
nucleic acid alone does not necessarily imply infectivity (58).
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Several studies have shown that viral nucleic matter can still
be quantified in diseases such as SARS-CoV-1, MERS, influenza
virus, Ebola virus, Zika virus, etc. even though the viable virus
cannot be detected (59–63) and in fact, measles viral RNA can
still be detected 6–8 weeks after the clearance of infectious virus.
It is believed that the immune system can neutralize viruses by
solubilizing or disintegrating the viral envelope or aggregating
virus particles; thus, preventing viral transmission without
eliminating nucleic acid, which eventually degrades (59–63).
This is because the detection methods of nucleic acids, i.e., the
PCR method cannot be used to differentiate between infectious
virus and non-infectious RNA. Thus, PCR findings should be
interpreted with care and caution must be exercised especially
when taking decisions on isolation policies, as infectivity data are
critical to demonstrate these specific aspects.
The critical question in the ensuing discussion so far in this
review, is how long a person continues to shed infectious virus?
In order to answer this question, it is important to note that
the determinant of infectious virus is not the detection of sub-
genomic RNA which is widely used in testing centers, but in vitro
infectiousness on cell lines by replication competent virus is
regarded as a more informative surrogate of viral transmission
(64–66). A number of studies have demonstrated that infectious
virus could not be detected in respiratory tract samples obtained
more than 8 days after onset of symptoms despite continued
detection of high levels of viral RNA (8, 67). This is the evidence
that gives credence to the WHO patient discharge protocol.
However, new evidence has emerged, suggesting that in patients
with severe to critical cases shedding infectious virus for more
than 10 days are common, due to their higher viral loads. Liu
et al. (11, 49) reported a single case of mild COVID-19 in
which infectious viruses were reported for 18 days after the onset
of symptoms.
Van Kampen et al. (30) studied 690 respiratory samples from
129 severe to critical patients using cell culture assay, viral RNA
load with RT-qPCR as well as measurement of neutralizing
antibody titres. Infectious SARS-CoV-2 was isolated from 62
respiratory tract samples of 23 patients in which detection of
infectious virus was common after 8 days or more since onset
of symptoms. For a single patient, infectious virus was detected
up to 20 days after onset of symptoms. Shedding of infectious
virus up to 18 days after onset of symptoms has been reported
for a single case of mild COVID-19 (11, 49). Higher viral loads
have been reported for severe COVID-19 cases compared to
mild cases, which may in part explain the longer duration of
shedding found in this study (6, 11, 26, 68). Kim et al. (55)
studied 20 patients, of which 11 had severe COVID-19. A total
of 78 samples were collected from the 20 patients; 57 samples
at various time periods. Viral RNA was detected for up to 78
days after the onset of symptoms. However, viable virus was
detected in 10 of 14 nasopharyngeal samples (71%). Out of these,
samples from 5 patients replicated viruses in culture for 8, 17,
25, 26, and 61 days after the onset of symptoms. Three patients
who shed live viruses for more than 20 days had profound
immunosuppression and had no neutralizing antibodies (were
seronegative) and were actually receiving hematopoietic cells
as therapy.
Economic challenges and prolonged turn-around times of
rRT-PCR-based testing makes it inadequate for post-discharge
screening of potentially infectious individuals. For these reasons,
antigen-based screening for SARS-CoV-2 is being considered
as a complement to rRT-PCR-based testing (69). Studies have
demonstrated sensitivity of SARS-CoV-2 Ag-RDTs between 22.9
and 93.9% compared to rRT-PCR (70–78). However, antigen-
based tests have been found to be comparable with culture-
based tests (79, 80). Separate reports by Kohmer et al. (81) and
Pekosz et al. (82) have recently shown that large-scale SARS-
CoV-2 Ag-RDT-based point-of-care testing can be considered for
detecting potentially contagious virus and reduce SARS-CoV-2
transmission. In light of these reports, we believe that SARS-
CoV-2 antigen testing, if deployed for post-discharge screening
of COVID-19 patients particularly in resource-limited settings,
can facilitate cost-effective and timely detection of individuals
harboring infectious viruses as well as provide risk determination
of the present WHO discharge guidelines.
INFLUENCE OF ENVIRONMENTAL
FACTORS ON VIRAL TRANSMISSION AND
VIABILITY
The most common mode of human to human transmission is
via body fluid droplets, infected hands and surfaces (83). The
SARS-CoV-2 virus was still infectious after 3 h when dispersed in
aerosols while it showed higher viability of 4, 24 and 72 h in the
form of droplets on copper, cardboard, plastic and stainless steel,
respectively (84). In contrast, the viability of the virus in aerosols
was only 3 h (84). In addition, SARS-CoV-2 virus was found to be
stable for 2 and 7 days on rough surfaces (fabric and wood) and
smooth surfaces (steel and plastic), respectively (85).
Environmental conditions including temperature, humidity,
wind speed, water, sewage, air, insects, and surface of objects
influence the viral transmission process. The prevalence of
COVID-19 with maximum air humidity and wind speed was
found to be negligible (86) while prevalence decreased with
increasing temperature, with unit increase in the minimum
surrounding air temperature resulting in a 0.86% decrease in
the cumulative number of cases (16). In another study, the daily
mortality of COVID-19 was negatively associated with absolute
humidity (87). Following investigation in Chinese andUSA cities,
a decrease in reproductive number (R) of SARS-CoV-2 was noted
with increased temperature and humidity (88).
Few studies have tried to investigate the correlation between
air pollution and COVID-19 cases. Wu et al. (89) observed that
a slight increase (1 µg/m3) in the concentration of particulate
matter increased the number of COVID-19 fatalities. In line with
this, in a cross-sectional nationwide study, Liang et al. (90) found
showed that COVID-19 participants who were exposed to NO2
for a long time had higher death probability (90). Furthermore,
up to 78% of 4,443 COVID-19 fatality cases considered by Ogen
(91) corresponded to main NO2 hotspots in Europe. Similarly,
Zhu et al. (92) found that short term exposure to air pollutants
such as PM2.5, PM10, CO, NO2, and O3 led to increased risk
of COVID-19 infection. In summary, most studies indicate that
Frontiers in Medicine | www.frontiersin.org 7 June 2021 | Volume 8 | Article 648660
Badu et al. SARS-CoV-2 Viral Shedding & Transmission Dynamics
patients developed more severe forms of COVID-19 when they
were exposed to air pollutants for long time and also took longer
to recover and had increased mortality rates.
CDC has not identified food, food packages, and food
handlers as a major mode of viral transmission. However,
washing and disinfection of surfaces is highly recommended
based on evidence suggesting the persistence of the virus for
hours/days (93). Most importantly, complete personal hygiene
such as covering the nose and mouth when sneezing/ coughing
is recommended for food handlers and those involved in food
preparation. The detection of SARS-CoV-2 RNA in sewage, even
though at low concentration shows that the virus can survive in
wastewater (94).
In addition to environmental factors, human population
density and movement, social interactions, climate change also
impacts on viral transmission.
RECOMMENDATIONS
The WHO played an important role in issuing guidelines and
measures to control the worldwide COVID-19 pandemic. In line
with this, the latter provided a first set of recommendations
for the discharge of COVID-19 patients. Due to challenging
conditions and poor infrastructure in many countries, these
recommendations were reviewed. Following a critical assessment
of follow-up studies involving convalescing COVID-19 patients,
we posit that there is no strong evidence which counters the
current WHO recommendations. However, we propose the
use of a test-based discharge strategy in immunocompromised
individuals. RT-PCR tests are less reliable. Indeed, false-negative
have been reported due to poor quality specimen collection,
testing too early in the incubation period, and other processing
errors. LRT specimens were shown to be more sensitive
compared to URT ones. Viral loads could be correlated with
disease severity with higher viral loads noted for severe forms
of COVID-19. However, viral load and viral shedding cannot
be directly correlated with infectivity because RT-PCR based
assays do not distinguish between degraded viral genetic remains
or viable virus. In patients with critical COVID-19, infectious
virus may be shed for longer periods in contrast to the
WHO guidelines. It has been observed that in the presence of
serum neutralizing antibodies, infectious virus shedding drops
to undetectable levels below a viral RNA load threshold. This
suggests that quantitative viral RNA load and immunological
assays are better alternatives in test-based approaches when
deciding to relax infection prevention and control precautions.
Van Kampen et al. (30) observed that once the serum neutralizing
antibody titer of at least 1:80 is achieved, infectious viruses could
not be isolated from respiratory tract samples of patients. These
pieces of evidence suggest that serological assays and quantitative
viral loads must be used in test-based policies when deciding to
ease control or prevention methods.
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